|
1kits (Ebipipa 10) .
| Omuwendo: | |
|---|---|
▎ Enzimba ya Cagrilintide
Ensibuko: PubChem |
Omutendera: Pyr-KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP CAS: 1415456-99-3 ku ssimu Ensengekera: C 174H 269N 45O 52S2 MW 4409 g/mol |
▎ Okunoonyereza ku Cagrilintide
Kiki ekiva mu kunoonyereza ku Cagrilintide?
Cagrilintide ye dual amylin ne calcitonin receptor agonist (DACRA) eyakolebwa okusinziira ku nsengekera ya amylin. Amylin efulumizibwa obutoffaali bwa pancreatic islet β era akolagana ne insulin okukola emirimu egy’enjawulo egy’omubiri. Kiyinza okuleeta okuwulira ng’okkuta n’okukendeeza ku mmere gy’olya, okusinga nga kikola ku bikwata mu kitundu postrema ku musingi gw’ekisenge eky’okuna. Obubonero bw’obusimu buyisibwa mu bwongo obw’omu maaso nga buyita mu nyukiliya y’omukutu ogw’omuntu omu era busobola n’okutambuzibwa mu kitundu kya hypothalamic eky’ebbali n’ebibinja bya nyukiliya ebirala nga buyita mu kitundu kya parabrachial eky’ebbali, bwe kityo ne kicamula ekifo eky’okukkuta n’okuziyiza okulya emmere [1] . Amylin era esobola okutereeza glucose homeostasis nga eziyiza okufulumya insulin ne glucagon okukuuma emiwendo gya glucose mu musaayi nga gitebenkedde [2] . Enkola zaayo mulimu okukwata obutereevu ku butoffaali bwa pancreatic islet α n’okulungamya obutatereevu okufuluma kwa glucagon okuyita mu bubonero bw’obusimu mu hypothalamus. Mu balwadde ba ssukaali, okusaanyaawo obutoffaali bwa β kivaako okukendeera kw’okufulumya amylin. Amylin yeetaba mu kulungamya glucose homeostasis nga eziyiza okufulumya amazzi mu lubuto n’okukola glucose mu kibumba oluvannyuma lw’okulya, okukendeeza ku nkyukakyuka za glucose mu musaayi oluvannyuma lw’okulya. Era kiyinza okulwawo okufulumya amazzi mu lubuto, okuziyiza okuzimba olubuto, okuwangaaza obudde emmere gy’emala, n’okuziyiza glucose mu musaayi okulinnya ennyo. Wabula ekitundu ky’obulamu ekitono ekya amylin ow’obutonde kikoma ku kukozesebwa kwayo mu bujjanjabi. Wadde nga pramlintide esangibwa ng’eddagala eriyamba, yeetaaga empiso ssatu olunaku, ekizibu era ekivaamu okugoberera obubi [3] . Okusobola okukola ku nsonga eno, Cagrilintide yakolebwa. Okunoonyereza n’okukulaakulanya kwayo kwesigamiziddwa ku kutegeera okw’amaanyi ku mirimu gy’omubiri egya amylin ow’obutonde, nga kigendereddwamu okukoppa enkola yaayo ey’okukola ate nga erongoosa obutebenkevu n’ebintu ebiwangaala eby’eddagala lino okusobola okutuukiriza ebyetaago by’obujjanjabi.
Cagrilintide kye ki?
Cagrilintide ye novel long-acting amylin analog nga erina obusobozi bungi, nga yalaga dda obulungi mu kusooka mu kujjanjaba omugejjo ne sukaali. Kibadde kifuuse amafuta era nga kirina engeri ezitebenkedde era ezikola okumala ebbanga [3] . Amylin efulumizibwa wamu ne insulini obutoffaali bwa β obw’olubuto era ereeta okuwulira ng’okkuta ng’ekola ku bitundu by’obwongo ebiyitibwa homeostatic ne pleasure. Nga analog, Cagrilintide esobola okukoppa ekikolwa kino, okuleeta okukkuta okuyamba okufuga obuzito bw’omubiri. Mu kiseera kye kimu, nga dual amylin ne calcitonin receptor agonist (DACRA), eggibwa mu mugongo gwa amylin era erina enkola ey’enjawulo mu kulungamya enkyukakyuka mu mubiri.
Enkola y’enzimba ya Cagrinlintide
Ensibuko:PubMed [3] .
Biki ebikwatagana n’okukozesa Cagrilintide?
Mu kugezesebwa mu malwaliro, Cagrilintide efunye ebirungi mu kuleeta okugejja. Okugeza, mu multicenter, randomized, double-blind, placebo-controlled, and active comparator Phase 2 dose-finding trial, bw’ogeraageranya n’ekibinja kya placebo, ebitundu bya wakati eby’okugejja okuva ku ntandikwa mu buli kibinja kya dose ya Cagrilintide (0.3 - 4.5 mg) (6.0% - 10.8%) byali waggulu okusinga ebyo mu kibinja kya placebo (3.0%). Okugejja mu kibinja kya 4.5 mg nakyo kyali kinene okusinga mu kibinja kya liraglutide 3.0 mg (10.8% vs. 9.0%), ekiraga nti kiyinza okuba eky’okulonda ekirungi mu kuddukanya omugejjo [4] . Cagrilintide erina enkola ey’enjawulo naye ekwatagana ey’okukola bw’ogeraageranya ne GLP-1 receptor agonist semaglutide. Semaglutid ekendeeza ku njagala y’okulya, eyongera ku kufulumya insulini, n’okulwawo okufulumya amazzi mu lubuto ng’ekola ku bikwata GLP-1 mu hypothalamus, ate Cagrilintide eyongera okukendeeza ku njagala y’okulya ng’ekola ekirungo kya amylin. Okukozesa ebibiri bino byonna awamu kuyinza okuvaamu ekikolwa ekissiddwa waggulu, okutumbula ennyo ekikolwa ky’okugejja [5] . Okusinziira ku buzibu bw’omugejjo, obujjanjabi buno obw’okugatta wamu nkola ya nsaamusaamu era ekola bulungi.
Mu balwadde ba sukaali ow’ekika eky’okubiri, Cagrilintide era alaze obusobozi obulungi obw’okufuga glucose mu musaayi. Okunoonyereza mu malwaliro kulaga nti erina okutebenkera okulungi n’okukola obulungi mu kujjanjaba omugejjo ne sukaali ow’ekika eky’okubiri. Okugeza, mu kugezesebwa okw’obujjanjabi ku balwadde abalina sukaali ow’ekika eky’okubiri, okukozesa awamu Cagrilintide ne GLP-1 receptor agonist semaglutide kwalaga okufuga obulungi glucose mu musaayi n’okugejja [6] . Okugezesebwa okulala era kwalaga nti egumiikiriza bulungi n’obukuumi bwakyo nga ekozesebwa yokka oba nga egattibwa wamu ne semaglutide [6] , kubanga okutebenkera kw’eddagala lino kukwatagana nnyo n’okugumira eddagala lino n’obukuumi bwalyo.
Okugatta ku ekyo, Cagrilintide ebadde egumiikiriza bulungi mu kugezesebwa mu malwaliro. Mu kugezesebwa okw’okuzuula ddoozi okw’omutendera ogw’okubiri, emiwendo gy’okuyimirizaawo enkalakkalira mu buli kibinja ky’obujjanjabi gyali gifaanagana, okusinga olw’ebizibu ebibaawo. Wabula ebizibu ebisinga okuvaamu byali buzibu mu lubuto n’engeri gye baakubye empiso, era ebisinga byali bitono oba bya kigero. Mu kugezesebwa okwa randomized, controlled Phase 1b, obujjanjabi obw’okugatta Cagrilintide ne 2.4 mg semaglutide nabwo bwalaga okugumiikiriza okulungi n’obukuumi [7] . Okugezesebwa okunene n’okumala ebbanga eddene kwetaagibwa mu biseera eby’omu maaso okwekenneenya mu bujjuvu obulungi n’obukuumi bw’obujjanjabi buno obw’omugatte.
Cagrilintide ereeta essuubi eppya mu kujjanjaba omugejjo ne sukaali ow’ekika eky’okubiri. Ewa obujjanjabi obupya eri abalwadde abagejjulukuka naddala abo abataddamu bulungi kuyingirira mu bulamu era nga tebasaanira kulongoosebwa bariatric. Enkola yaayo ey’enjawulo ey’okukola etuwa ebirowoozo ebipya n’enkola ez’okujjanjaba omugejjo, era eyinza okuba n’ebirungi bingi okusinga eddagala ery’ekinnansi erikendeeza ku mugejjo (D’Ascanio AM, 2024). Ensonga ewangudde ey’okukozesa okugatta Cagrilintide ne semaglutide (CagriSema) eraga nti obujjanjabi obw’okugatta ebigendererwa ebingi nkola nnungi okulongoosa okuddamu kw’obujjanjabi eri omugejjo [6] . Omuze guno guwa enkola empya ey’okuddukanya omugejjo era era guleeta okulongoosa okw’amaanyi mu nkyukakyuka y’emmere eri abalwadde abalina ssukaali ow’ekika eky’okubiri.
Mu kumaliriza, nga novel long-acting amylin analog, Cagrilintide erina obusobozi obw’amaanyi mu kugejja n’okufuga glucose mu musaayi. Ekola ekkubo ly’obubonero bw’okukkuta nga ekoppa ekikolwa kya amylin era n’etereeza enkyukakyuka mu mubiri nga dual receptor agonist. Okugezesebwa mu malwaliro kulaga nti Cagrilintide, oba yekka oba nga egattibwa ne semaglutide, esobola okukendeeza ennyo ku buzito bw’omubiri era egumiikiriza bulungi. Okugatta ku ekyo, era eraze obusobozi obulungi mu kufuga glucose mu musaayi mu balwadde ba sukaali ow’ekika eky’okubiri, okuwa enkola empya ey’obujjanjabi ey’okujjanjaba omugejjo ne sukaali, okuziba ekituli mu nkola z’obujjanjabi eziriwo naddala eri abalwadde abataddamu bulungi kuyingirira mu bulamu era nga tebasaanira kulongoosebwa. Enkola yaayo ey’obujjanjabi ey’ebigendererwa ebingi etuwa ebirowoozo ebipya ku nzirukanya y’endwadde z’enkyukakyuka mu mubiri.
Ebikwata ku Muwandiisi
Ebintu ebyogeddwako waggulu byonna binoonyerezeddwako, birongooseddwa era ne bikung’aanyizibwa kkampuni ya Cocer Peptides.
Omuwandiisi wa Scientific Journal
Dr. DCW Lau pulofeesa mu ssomero ly’obusawo erya Cumming School of Medicine, mu yunivasite y’e Calgary mu Canada. Okunoonyereza kwe kukwata ku endocrinology ne metabolism, eddagala erya bulijjo n’ery’omunda, enkola y’emisuwa n’omutima, ebyobulamu by’abantu, ebyobulamu by’obutonde n’emirimu, wamu n’eby’obulwadde bwa kookolo. Era alina ebifo mu kkampuni ya Alberta Health Services (AHS) ne Obesity Canada era akolera mu kitongole ekinoonyereza ku ssukaali ekya Julia McFarlane. Dr. Lau alina obumanyirivu bungi mu kunoonyereza ku ssukaali n’omugejjo, ng’emirimu gye gifulumizibwa mu bitabo by’abayivu nga Canadian Journal of Diabetes. Dr. DCW awandiikiddwa mu kiwandiiko ekijuliziddwa mu kiwandiiko ekijuliziddwa [4].
